Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR

Megumi Funakoshi-Tago1, Takuro Moriwaki1, Fumihito Ueda1

  • 1Department of Hygienic Chemistry, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan.

Cellular Signalling
|January 1, 2017
PubMed

Insights

Cytokine-inducible Src homology 2 protein (CIS) acts as a tumor suppressor in myeloproliferative neoplasms (MPNs) by inhibiting JAK2 V617F signaling. Its enforced expression reduces tumor formation and induces apoptosis, highlighting its therapeutic potential.

Area of Science:

  • Molecular Biology
  • Oncology
  • Signal Transduction

Background:

  • Myeloproliferative neoplasms (MPNs) are characterized by aberrant JAK2 V617F signaling.
  • Negative regulators of the JAK-STAT pathway, such as CIS and SOCS, are implicated in MPNs, but their specific roles are unclear.

Purpose of the Study:

  • To elucidate the functional role of CIS and SOCS family members in JAK2 V617F mutant-induced oncogenic signaling.
  • To investigate the mechanism by which CIS suppresses tumor formation in MPNs.

Main Methods:

  • RNA interference (RNAi) to silence CIS and SOCS1 expression.
  • Enforced expression of CIS in JAK2 V617F mutant-transformed cells.
  • Analysis of STAT5 and ERK activation.
  • Assessment of tumor formation in nude mice.
  • Investigation of CIS interaction with phosphorylated EpoR and its SH2 domain function.

Main Results:

  • CIS expression is induced by STAT5 activation in JAK2 V617F mutant cells.
  • Silencing CIS enhanced cell proliferation and tumor formation; silencing SOCS1 had no effect.
  • Enforced CIS expression inhibited tumor formation and induced apoptosis.
  • CIS interacts with phosphorylated EpoR, inhibiting STAT5 and ERK activation.
  • CIS's anti-tumor effects depend on its SH2 domain and tyrosine phosphorylation at Y253.

Conclusions:

  • CIS functions as a novel tumor suppressor in JAK2 V617F mutant-induced tumorigenesis.
  • CIS inhibits oncogenic signaling by interacting with phosphorylated EpoR, thereby suppressing STAT5 and ERK activation.
  • Targeting CIS may offer a therapeutic strategy for MPNs.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.5K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
19.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K